ArticleCell reports2026
Wntless degradation mediated by CaMKII inhibition drives endoplasmic reticulum stress and apoptosis.
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Noncanonical Wnt signaling stimulates calcium release and subsequent activation of calcium/calmodulin-dependent protein kinase 2 (CaMKII). We find that CaMKII inhibition decreases Wnt synthesis and identify the downregulation of Wntless (WLS) as the basis for this decrease. WLS transports palmitoylated Wnts to the cell surface, and in the absence of Wnts, it undergoes endoplasmic reticulum (ER)-associated degradation (ERAD). CaMKII inhibition increases proteasome-dependent WLS degradation, which can be suppressed by Wnt overexpression, indicating that CaMKII contributes to ER handling of unliganded WLS and prevention of ERAD. CaMKII inhibition also causes a loss of calnexin, an ER stress response through the activation of PERK, and apoptosis in cells expressing high levels of WLS. Moreover, these effects can be prevented by WLS knockdown. The findings reveal a previously unidentified role for CaMKII in supporting ER chaperone functions. They further show that high levels of unliganded WLS could be a potent driver of ER stress in the presence of CaMKII inhibitors, which may have efficacy in tumors expressing high levels of WLS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.